Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus placebo maintenance after MPV induction in newly diagnosed multiple myeloma
2013-001729-26Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Lenalidomide maintenance with Placebo maintenance (2 arms). Primary endpoint: Overall survival. Started Jan 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-001729-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001729-26.